Budesonide to prevent engraftment syndrome after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This Phase 3 study tests whether budesonide can prevent “engraftment syndrome” after people receive a hematopoietic (blood-forming) stem cell transplant. If it works, it may reduce complications around the time the new cells start growing and making blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 80 years old
- Have a blood cancer diagnosis (a hematologic malignancy)
- Be someone who your transplant program would approve for a stem cell transplant for a blood cancer
- Not be currently enrolled in another research (investigational) clinical trial
- Your stem cell transplant must be for a blood cancer (not for a non-blood cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people who have had a donor stem cell transplant and then develop a condition called engraftment syndrome, where the new immune cells cause symptoms like fever, rash, or swelling. The goal is to learn more about the different types of this condition and how it affects recovery, so doctors can better predict and manage outcomes.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This Phase 2 study tests whether budesonide can lower the chance of moderate-to-severe diarrhea in people with multiple myeloma who are getting an autologous stem cell transplant. It may help your comfort and reduce complications during the transplant recovery period.
This early-phase study tests whether giving the drug bendamustine (with or without another chemo drug) can lower the risk of graft-versus-host disease (GVHD) after a stem cell transplant. GVHD is an immune reaction where the donor’s cells attack your body. If it works and is safe, it could improve outcomes after transplant.
This trial tests whether using an inhaled steroid (budesonide) can help prevent lung inflammation (pneumonitis) from coming back in people who have had it caused by immunotherapy cancer treatment. It may be an option for patients who need extra support after their first bout of this side effect.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Hear when a new Engraftment Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.